A phase I randomized, investigator and participant-blind, adaptive, multiple-ascending dose, parallel and four-way crossover, placebo-controlled study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, and drug interactions (with midazolam) of RO7308480 following oral administration in healthy participants.

2023-504794-20-00 Protocol BP43804 Human pharmacology (Phase I) - Other Ended

Start 26 Oct 2023 · End 17 Jul 2024 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol BP43804

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 100
Countries 1
Sites 1

Healthy participants (part 1 and part 2)

Key facts

Sponsor
F. Hoffmann-La Roche AG
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Psychiatry and Psychology [F] - Behavioral Disciplines and Activities [F04]
Trial duration
26 Oct 2023 → 17 Jul 2024
Decision date (initial)
2023-10-23
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Healthy participants (part 1 and part 2)

VersionLevelCodeTermSystem organ class
21.1 PT 10041242 Social anxiety disorder 100000004873

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

F. Hoffmann-La Roche AG

Sponsor organisation
F. Hoffmann-La Roche AG
Address
Grenzacherstrasse 124
City
Basel
Postcode
4058
Country
Switzerland

Scientific contact point

Organisation
F. Hoffmann-La Roche AG
Contact name
Head of CTRM , Clinical Trial Regulatory Management, Product Development Regulatory

Public contact point

Organisation
F. Hoffmann-La Roche AG
Contact name
Head of CTRM , Clinical Trial Regulatory Management, Product Development Regulatory

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
France Ended 100 1
Rest of world 0

Investigational sites

France

1 site · Ended
Biotrial
Unité Clinique, 7 Rue Jean Louis Bertrand, 35000, Rennes

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
France 2023-10-26 2024-07-17 2023-10-26 2024-07-17

Application history

3 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2023-07-13 France Acceptable
2023-10-16
2023-10-23
2 SUBSTANTIAL MODIFICATION SM-1 2023-12-11 France Acceptable
2024-04-05
2024-04-09
3 NON SUBSTANTIAL MODIFICATION NSM-1 2024-05-28 France Acceptable
2024-04-05
2024-05-28